Last reviewed 2026-04-20 · How we verify

Hexadiphane (PROZAPINE)

Phase 2 active Small molecule

Hexadiphane (generic name: PROZAPINE) is a prozapine drug. It is currently in Phase 2 development.

Prozapine is thought to work by interacting with cellular pathways, although the exact mechanism is unknown.

Hexadiphane, also known as Prozapine, is a small molecule drug in the prozapine class. Its exact target and mechanism of action are unknown, but it is believed to work by interacting with certain cellular pathways. Prozapine is not FDA-approved for any indications, and its commercial status, including patent status and generic availability, is unclear. Further research is needed to fully understand its potential therapeutic applications and safety profile. As a result, key safety considerations and dosing information are not well established.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	PROZAPINE
Drug class	prozapine
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your cells as a complex network of roads and intersections. Prozapine is like a traffic controller that helps regulate the flow of information and materials within the cell. By doing so, it may help to modulate various cellular processes, although the precise details of how it does this are still unclear.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Hexadiphane CI brief — competitive landscape report
Hexadiphane updates RSS · CI watch RSS

Frequently asked questions about Hexadiphane

What is Hexadiphane?

Hexadiphane (PROZAPINE) is a prozapine drug.

How does Hexadiphane work?

Prozapine is thought to work by interacting with cellular pathways, although the exact mechanism is unknown.

What is the generic name of Hexadiphane?

PROZAPINE is the generic (nonproprietary) name of Hexadiphane.

What drug class is Hexadiphane in?

Hexadiphane belongs to the prozapine class. See all prozapine drugs at /class/prozapine.

What development phase is Hexadiphane in?

Hexadiphane is in Phase 2.

Drug class: All prozapine drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing